The report covers forecast and analysis for the market on a global and regional level. The study provides historic data of hepatitis C drug market 2015 along with a forecast from 2016 to 2021 based on revenue (USD billion). The study includes drivers and restraints for the hepatitis C drug market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the hepatitis C drug market on a global level.
In order to give the users of this report a comprehensive view on the hepatitis C market, we have included a detailed competitive scenario and type portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter&rsquos Five Forces model for the hepatitis C drug market has also been included. The study encompasses a market attractiveness analysis, wherein application segments are benchmarked based on their market size, growth rate and general attractiveness.
The study provides a decisive view on the hepatitis C drug market by segmenting the market based on applications. All the application segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021. Hospitals, private labs, physician offices, public health labs, and blood banks are the key application of the hepatitis C drug market. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East & Africa with its further bifurcation into major countries including U.S., Canada, Germany, France, UK, China, Japan, India and Brazil. This segmentation includes demand for hepatitis C drug based on individual applications in all the regions and countries.
Some of the key player in the hepatitis C drug market includes Merck & Co, Kenilworth, Roche, Basel GlaxoSmith, Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb.
The report segments the global hepatitis C drug market as
Hepatitis C Drug Market: Application Segment Analysis
Hospitals
Private labs
Physician offices
Public health labs
Blood banks
Hepatitis C Drug Market: Regional Segment Analysis
North America
U.S.
Europe
Germany
UK
France
Asia Pacific
China
Japan
India
Latin America
Brazil
Middle East and Africa
Table of Content
Chapter 1. Preface
1.1. Report description and scope
1.2. Research scope
1.3. Research methodology
1.3.1. Market research process
1.3.2. Market research methodology
Chapter 2. Executive Summary
2.1. Global hepatitis C drug market, 2015 - 2021, (USD Billion)
2.2. Hepatitis C drug: market snapshot
Chapter 3. Hepatitis C Drug Market: Industry Analysis
3.1. Hepatitis C drug : Market dynamics
3.2. Market Drivers
3.2.1. Increasing incidences of the disease
3.2.2. New efficient therapies and comparatively smaller period of treatment
3.2.3. Rising government funding
3.3. Restraints
3.3.1. Lack of awareness and information about HCV
3.3.2. Treatment cost
3.3.3. Threat related with regulation and development of drug
3.4. Opportunity
3.4.1. Advancing technologies and ongoing research
3.5. Porter’s Five Forces Analysis
3.6. Market Attractiveness Analysis
3.6.1. Market attractiveness analysis by application segment
3.6.2. Market attractiveness analysis by regional segment
Chapter 4. Global hepatitis C drug market: Competitive Landscape
4.1. Company Market Share Analysis
4.1.1. Global hepatitis C drug market: company market share, 2015
4.2. Strategic Development
4.2.1. Acquisitions Mergers
4.2.2. New Product Launch
4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
4.2.4. Research and Development, Product and Regional Expansion
4.3. Price Trend Analysis
4.4. Product Portfolio
4.5. Patent Analysis (2011-2016)
4.5.1. Patent Trend
4.5.2. Patent Share by company
4.5.3. By Region
Chapter 5. Global hepatitis C market: Application Overview
5.1. Global hepatitis C drug market share, by application, 2015 and 2021
5.2. Global hepatitis C drug market for hospitals, 2015 - 2021(USD Billion)
5.3. Global hepatitis C drug market for private labs , 2015 - 2021 (USD Billion)
5.4. Global hepatitis C drug market for physician offices, 2015 - 2021 (USD Billion)
5.5. Global hepatitis C drug market for public health labs, 2015 - 2021 (USD Billion)
5.6. Global hepatitis C drug market for blood banks, 2015 - 2021 (USD Billion)
Chapter 6. Global hepatitis C drug market: Regional Analysis
6.1. Global hepatitis C drug market: Regional overview
6.1.1. Global hepatitis C drug market share, by region, 2015 and 2021
6.2. North America
6.2.1. North America hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
6.2.2. U.S.
6.2.3. U.S. hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
6.3. Europe
6.3.1. Europe hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
6.3.2. UK
6.3.2.1. UK hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
6.3.3. France
6.3.3.1. France hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
6.3.4. Germany
6.3.4.1. Germany hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
6.4. Asia Pacific
6.4.1. Asia-Pacific hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
6.4.2. China
6.4.2.1. China hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
6.4.3. Japan
6.4.3.1. Japan hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
6.4.4. India
6.4.4.1. India hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
6.5. Latin America
6.5.1. Latin America hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
6.5.2. Brazil
6.5.2.1. Brazil hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
6.6. Middle East Africa
6.6.1. Middle East Africa hepatitis C drug market revenue, by application, 2015 – 2021 (USD Billion)
Chapter 7. Company Profiles
7.1. Merck Co
7.1.1. Overview
7.1.2. Financials
7.1.3. Product portfolio
7.1.4. Business strategy
7.1.5. Recent developments
7.2. Kenilworth
7.2.1. Overview
7.2.2. Financials
7.2.3. Product portfolio
7.2.4. Business strategy
7.2.5. Recent developments
7.3. Roche
7.3.1. Overview
7.3.2. Financials
7.3.3. Product portfolio
7.3.4. Business strategy
7.3.5. Recent developments
7.4. Basel Glaxosmith
7.4.1. Overview
7.4.2. Financials
7.4.3. Product portfolio
7.4.4. Business strategy
7.4.5. Recent developments
7.5. Gilead Sciences
7.5.1. Overview
7.5.2. Financials
7.5.3. Product portfolio
7.5.4. Business strategy
7.5.5. Recent developments
7.6. Abbvie
7.6.1. Overview
7.6.2. Financials
7.6.3. Product portfolio
7.6.4. Business strategy
7.6.5. Recent developments
7.7. Bristol- Myers Squibb.d
7.7.1. Overview
7.7.2. Financials
7.7.3. Product portfolio
7.7.4. Business strategy
7.7.5. Recent developments
7.8. Johnson Johnson
7.8.1. Overview
7.8.2. Financials
7.8.3. Product portfolio
7.8.4. Business strategy
7.8.5. Recent Developments
Chapter 8. Patents
8.1. U.S. (US Patents)
8.2. Europe (EP documents)
8.3. Japan (Abstracts of Japan)
8.4. Global (WIPO (PCT))
